The US Senate Judiciary Committee urged the Federal Trade Commission to launch a probe into whether Mylan engaged in anticompetitive practices by preventing schools from purchasing competing allergy treatments to its EpiPen (epinephrine) product. "Due to the dramatic increase of the price of drugs across the board, the FTC should be vigilant in its scrutiny of this market," the lawmakers wrote.
The request comes ahead of a meeting of the committee to review a pending $465 million settlement that Mylan recently reached with the Department of Justice to settle claims related to the classification of EpiPen under the Medicaid rebate programme.
In response to the latest news, a Mylan spokeswoman defended the company's EpiPen4Schools programme, noting that it has no purchase requirement for schools to participate and that it offers schools four free EpiPens per calendar year also without purchase restrictions. The spokeswoman added that while previously schools that wished to purchase additional EpiPens could do so in some cases with a discount and a "limited purchase restriction," no such restriction are now in place.
Meanwhile, in another letter sent to Mylan three members of the Senate Judiciary Committee asked the company when it plans to reimburse the Department of Defense for any overcharging on EpiPen.
To read more Top Story articles, click here.